Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1

Status

Completed 22Terminated 8Active not recruiting 4Unknown 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 4Urogenital Neoplasms 1Neoplasm Metastasis 1

Interventions

pembrolizumab 85Specimen Handling 79Carboplatin 74Magnetic Resonance Spectroscopy 71Biopsy 58Nivolumab 55Cisplatin 55Paclitaxel 46Cyclophosphamide 45durvalumab 38Radiotherapy 36Radiation 35olaparib 34Rituximab 34Etoposide 33Dexamethasone 33Ipilimumab 30Gemcitabine 30Lenalidomide 28Doxorubicin 28Taxes 27Pemetrexed 27Docetaxel 27Bevacizumab 25Prednisone 24Cytarabine 23X-Rays 22Trastuzumab 21cabozantinib 20Disulfides 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × Has results × abiraterone × Clear all
NCT04262154 2026-05-11

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
28 enrolled 9 charts
Genitourinary

Prostatic Neoplasms

NCT04647526 2026-01-13

SPLASH

Eli Lilly and Company

Phase 3 Active not recruiting
455 enrolled 18 charts
Genitourinary

Prostatic Neoplasms

NCT04446117 2025-12-18

CONTACT-02

Exelixis

Phase 3 Active not recruiting
575 enrolled 13 charts
Genitourinary

Prostatic Neoplasms

NCT05288166 2025-06-27

CYCLONE 3

Eli Lilly and Company

Phase 3 Active not recruiting
925 enrolled 12 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡